Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Keytruda In Combination With Inlyta Reduced Risk Of Death By Nearly Half Compared To Sunitinib As First-Line Treatment For Advanced RCC

Merck & Co. announced presentation of the full results from the pivotal Phase 3 KEYNOTE-426 trial investigating the company’s anti-PD-1 therapy Keytruda in combination with Inlyta, a tyrosine kinase inhibitor, for the first-line treatment of advanced renal cell carcinoma (RCC) at the 2019 Genitourinary Cancers Symposium.

Read More »

Phase 3 ARCHES Trial Shows Xtandi Significantly Improved Radiographic Progression-Free Survival in Men with mHSPC

Pfizer Inc. and Astellas Pharma Inc. announced results from the Phase 3 ARCHES trial in men with metastatic hormone-sensitive prostate cancer (mHSPC).

Read More »

Opdivo Plus Low-Dose Yervoy Demonstrates Continued Survival Benefit at 30-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic RCC

Bristol-Myers Squibb Company announced new results from the Phase 3 CheckMate -214 study, showing that therapy with Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) continued to demonstrate long-term survival benefits in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC).

Read More »

Samsung Bioepis and C-Bridge Capital to Develop and Commercialize Next-Generation Biosimilars in China

Samsung Bioepis Co. Ltd. announced the company’s expansion in mainland China through a licensing agreement with C-Bridge Capital. The transaction covers multiple biosimilar candidates from Samsung Bioepis, including third-wave biosimilar candidates SB11 and SB12 – which reference Lucentis (ranibizumab) and Soliris (eculizumab) – as well as the biosimilar candidate SB3 that references Herceptin (trastuzumab).

Read More »

Cidara Therapeutics Announces Rezafungin Presentations at the 2019 Transplantation and Cellular Therapy (TCT) Meeting

Cidara Therapeutics Inc. announced that data from studies of the biotechnology company’s lead antifungal rezafungin will be presented at the 2019 Transplantation and Cellular Therapy (TCT) Meeting of ASBMT and CIBMTR to be held in Houston from Feb. 20-24.

Read More »

Dr. Reddy’s Announces the Appointment of Marc Kikuchi to Lead Its Generics Business in North America

  February 01, 2019 10:17 AM Eastern Standard Time   HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE: RDY), along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the appointment of Marc Kikuchi as Chief Executive Officer, North America Generics. As part of the Dr. Reddy’s […]

Read More »

FDA approves Dr. Reddy’s Tosymra

Dr. Reddy’s Laboratories Ltd. and its subsidiary, Promius Pharma LLC, announced the approval of Tosymra (previously known as DFN-02) by the U.S. Food and Drug Administration.

Read More »

European Commission Approves Clovis Oncology’s Rubraca Tablets as Maintenance Treatment for Relapsed Ovarian Cancer

Clovis Oncology Inc. announced that the European Commission approved the use of Rubraca (rucaparib) for a second indication: as monotherapy for the maintenance treatment of adults with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.

Read More »

FDA Clears First Diagnostic Test to Detect Emerging Health Threat Mycoplasma genitalium

Hologic Inc. announced that the U.S. Food and Drug Administration granted clearance for the company’s Aptima Mycoplasma genitalium assay, the first FDA-cleared test to detect this under-recognized but increasingly common sexually transmitted infection (STI).

Read More »

AbelsonTaylor Launches ICONS.HEALTH

What do Microsoft, Aetna, Twitter, IBM, Ogilvy Consulting, Biogen and dozens of healthcare startups have in common? All appear in discussions about issues at the nexus of healthcare and technology in Icons.Health, a new video series produced by AbelsonTaylor.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!

Subscribe

Ad Right Bottom